Login ID:
Password:
Partner Login
Contact Us : 7066511911

Press Release: Bayer Appoints Dr. Sharon James Head of Global Innovation & Development for Consumer Health

22 Sep 2017 9:28 am
Bayer Appoints Dr. Sharon James Head of Global Innovation & Development 
for Consumer Health 
 
 
   PR Newswire 
 
 
   BASEL, Switzerland, Sept. 22, 2017 
 
 
   BASEL, Switzerland, Sept. 22, 2017 /PRNewswire/ -- Bayer today announced 
the appointment of Dr. Sharon James as Head of the Global Innovation & 
Development (I&D) organization of the Consumer Health Division, 
effective October 2, 2017.  Dr. James succeeds Dr. John O'Mullane, who 
will retire from the company on December 31, 2017 after 30 years in the 
industry. 
 
 
 
   "With more than 25 years' experience in the fast-moving consumer goods 
and consumer product sector, Sharon has a proven record of developing 
and supporting products for leading consumer brands," said Erica Mann, 
Member of the Board of Management, Bayer AG, and President, Consumer 
Health Division, Bayer. "I am excited that Sharon is joining Consumer 
Health, and know that under her leadership Bayer will continue to 
successfully develop and deliver new innovative self-care solutions that 
help people around the world be a little healthier every day." 
 
 
   Dr. James joins Bayer from Reckitt Benckiser, where she most recently 
held the position of Senior Vice President, Head of Global Research & 
Development (R&D), at the company's global headquarters in Slough, UK. 
She also previously held various senior roles at PepsiCo and Glaxo 
SmithKline. 
 
 
   Dr. James' product development experience spans health, personal and 
home care categories where she has delivered transformative and 
consumer-loved innovation internationally. Known for embedding a 
'consumer-first' mindset in R&D, Dr. James is also a strong advocate of 
open innovation -- collaborating extensively with a broad range of 
partners across the health industry. 
 
 
   Dr. James holds a Ph.D. in Neurobiology from University College London, 
Department of Anatomy and Developmental Biology and a Bachelor of 
Science degree in Medical Biochemistry from University of London. 
 
 
   Dr. James will report to Erica Mann and will be a member of the Consumer 
Health Executive Committee. She will be based in Basel, Switzerland. 
 
 
   Dr. O'Mullane joined Bayer in 2014 following the acquisition of Merck 
Consumer Care. Among his many accomplishments leading global research 
and development organizations at Bayer, Merck (MSD) as well as 
Schering-Plough and GlaxoSmithKline, was leading successful 
over-the-counter switches of prescription medicines, creating 
state-of-the-art consumer testing centers at company facilities, and 
establishing consumer-centric design thinking methodologies across the 
function. Additionally, at Bayer, Dr. O'Mullane led a strategy to 
sharpen the Division's focus and redesign its innovation and development 
operating model to better deliver bigger, better and faster innovation 
to consumers. 
 
 
   "Under John's leadership, the Division is well-prepared to meet the 
needs and desires with new products that consumers demand," said Erica 
Mann. "I would like to thank John for his passion and strong sense of 
purpose that has helped to put us on a path of even greater success with 
our innovation efforts." 
 
 
   Bayer: Science For A Better Life 
 
 
   Bayer is a global enterprise with core competencies in the Life Science 
fields of health care and agriculture. Its products and services are 
designed to benefit people and improve their quality of life. At the 
same time, the Group aims to create value through innovation, growth and 
high earning power. Bayer is committed to the principles of sustainable 
development and to its social and ethical responsibilities as a 
corporate citizen. In fiscal 2016, the Group employed around 115,200 
people and had sales of EUR 46.8 billion. Capital expenditures amounted 
to EUR 2.6 billion, R&D expenses to EUR 4.7 billion. These figures 
include those for the high-tech polymers business, which was floated on 
the stock market as an independent company named Covestro on October 6, 
2015. For more information, go to www.bayer.com. 
 
   Media Contact: 
 
   Trish McKernan, Bayer, Tel. +41 58-272-7871 
 
 
   E-mail: tricia.mckernan@bayer.com 
 
 
   View original content with 
multimedia:http://www.prnewswire.com/news-releases/bayer-appoints-dr-sharon-james-head-of-global-innovation--development-for-consumer-health-300524268.html 
 
 
 
   SOURCE Bayer 
 
 
    /Web site: http://www.bayer.us 
 
 
 
 

(END) Dow Jones Newswires

September 22, 2017 05:28 ET (09:28 GMT)
Disclaimer
Top 5 Special Reports
Weekly: ICE Raw Sugar Closes the Week over 9-Month on ...
Weekly: ICE Cotton Marks 2nd Weekly Gain on China Tarif...
Weekly: Urad, White/Green Pea Post Strong Gains As Cust...
U.S. Soy Exports Hit 2 Year High, As China’s Interest D...
Tamil Nadu Sugar Mill Prices – 06 December 2019